Events 11/16/23 「Announcement of “Japan-Korea Joint Symposium on Translational Research in Regenerative Medicine and Genome Editing”」
Event Information
Change log
Summary of Event
Focusing on translational research in the field of regenerative medicine (including genome editing technology and cell therapy), which is a strength of both Japan and South Korea's life sciences, we will invite experts from both countries in the fields to introduce the latest research from both countries. In addition to introducing research & development trends and achievements, we will exchange opinions on possibilities for future cooperation between the two countries.
This symposium will be a hybrid event where you can participate either on site or online.Name
「Japan-Korea Joint Symposium on Translational Research in Regenerative Medicine and Genome Editing」
Date & Time
Venue
Nihonbashi Life Science Building Room#201（Nihonbashi Honcho, 2-3-11, Chuo-ku, Tokyo, 103-0023）
- Online participation will be on a Zoom webinar. The URL will be provided to those who have registered to participate.
Capacity
Onsite Participation: 100 people（Advance registration required: Registration will close once the capacity has been reached.）
Online Participation: 500 people（Advance registration required: Registration will close once the capacity has been reached.）
Fee
Free
How to Apply
Please apply from the links below and choose to participate at the venue or online.
(Registration deadline: Tuesday, November 15th, noon)
Please note that registration will end as soon as the capacity has been reached.
Please register for the event, click here.
Organizer
Japan Agency for Medical Research and Development (AMED)
The Korean Health Industry Development Institute (KHIDI)
Cooperation
The Japan Society of Gene and Cell Therapy (JSGCT)
The Japanese Society for Genome Editing (JSGE)
The Japanese Society for Regenerative Medicine (JSRM)
Life Science Innovation Network Japan (LINK-J)
Program
| Program | |
|---|---|
| Opening Remarks Greetings from organizers and guests |
President of AMED, President of KHIDI, MEXT |
| Mesenchymal stem cell derived extracellular vesicle therapy for liver cirrhosis. | Prof TERAI Shuji Graduate School of Medical and Dental Sciences Molecular and Cellular Medicine Cellular Function, Niigata University (Japan) |
| Developing iPSC-based cell therapy and drug screening for intractable neurological diseases | Prof SONG Jihwan, Cha University Founder & CEO, iPS Bio, Inc (Korea) |
| iPSCs-based Regenerative Medicine for CNS Disorders | Prof OKANO Hideyuki Department of Physiology, Keio University School of Medicine (Japan) |
| Next-generation Cell Therapy: Human Pluripotent Stem Cell-derived Mesenchymal Stromal Cells Genetically Engineered to Express AFFIMER® Proteins to Enhance the Immune Response | Dr RYU Jongsang, Chief Scientific Officer, AffyXell Therapeutics Co., Ltd. (Korea) |
| Precise Gene Editing in Rare Diseases | Associate Prof BAE Sangsu, Seoul National University College of Medicine (Korea) |
| Genome editing and delivery technologies for muscular dystrophy | Associate Prof HOTTA Akitsu Department of Clinical Application, Center for iPS Cell Research & Application (CiRA), Kyoto University (Japan) |
| Application of the Genetically Humanized Mouse Model to the Development of Gene Editing Therapy | Associate Prof SUNG YoungHoon, Convergence Medicine Research Center (CREDIT), Asan Institute for Life Sciences, Assan Medical Center/ Department of Cell and Genetic Engineering, University of Ulsan College of Medicine (Korea) |
| Swine in Biomedical Research | Prof HANAZONO Yutaka Translational Research Laboratory, Center for Development of Advanced Medical Technology, Jichi Medical University (Japan) |
| Panel Discussion Session | |
Contact
Japan-Korea Symposium Secretariat
Division of Strategic Planning
Department of International Strategy
Japan Agency for Medical Research and Development (AMED)
E-Mail：amed-khidi-20231116"AT"maxpart.co.jp
※Replace "at" with @".
Last updated 11/15/23